Tag: Biotech and Pharma

GSK shares jumped Wednesday on news Delaware’s top court ruled in the pharmaceutical company’s favor, by agreeing to review the admissibility of expert evidence that could play a part in the British firm’s legal fight against claims its Zantac heartburn drug causes cancer.

Eli Lilly on Tuesday released a new form of its weight loss drug Zepbound for roughly half its usual monthly list price to reach millions of patients without insurance coverage for the popular injection, such as those with Medicare

Shares of Danish biotech company Bavarian Nordic jumped 13% on Thursday after it reported stronger-than-expected earnings and announced a bumper vaccine order from an unnamed European country amid the ongoing mpox outbreak.

Eli Lilly’s highly popular weight loss drug reduced the risk of developing Type 2 diabetes by 94% in obese or overweight adults with prediabetes compared with a placebo, according to initial results from a long-term study released Tuesday.

GeoVax Labs Inc.’s stock soared 54% early Monday to lead a fresh rally among companies developing treatments for mpox, after rival Siga Technologies Inc. said a trial of its antiviral failed to meet its main goal.

Bayer shares jumped in morning trade as the German life sciences company said it scored a legal victory in its suit over claims that exposure to its popular Roundup weed killer led to cancer.

Danish biotech company Bavarian Nordic said Friday that it had submitted data to the Europe Union’s drug regulator to extend the use of its mpox vaccine for teenagers.

The biotech Gilead Sciences raised its earnings guidance Thursday while reporting second quarter results that beat Wall Street expectations, as the company continues to battle back from an early-year slump in its share price.

Eli Lilly on Thursday reported second-quarter earnings and revenue that blew past expectations and hiked its full-year revenue outlook by $3 billion as sales of its blockbuster diabetes drug Mounjaro and weight loss injection Zepbound spike.

 Novavax on Thursday cut its revenue forecast for 2024 as it anticipated lower sales of its COVID-19 vaccine, including the company’s updated shot for the fall season targeting the JN.1 variant.

Novo Nordisk on Wednesday posted weaker-than-expected net profit in the second quarter and trimmed its operating profit outlook.

Biogen on Thursday reported second-quarter earnings and revenue that topped estimates and hiked its full-year guidance, as the company’s cost cuts showed progress and sales of its breakthrough Alzheimer’s drug, Leqembi, and other new products beat expectations.

Moderna on Thursday reported second-quarter revenue that beat expectations but slashed its full-year sales guidance, citing lower expected sales in Europe, a “competitive environment” for respiratory vaccines in the U.S. and the potential for deferred international revenue into 2025. 

UK pharmaceutical group forecasts 7-9% revenue growth this year on strong performance from cancer and HIV drugs

Pfizer Inc.’s stock rose 2.7% early Tuesday, after the company blew past earnings estimates for the second quarter, offered an update on a cost-cutting plan and raised its revenue and profit guidance for the year.

Merck on Tuesday reported second-quarter revenue and adjusted earnings that topped Wall Street’s expectations as it saw strong sales from its blockbuster cancer drug Keytruda as well as other treatments in its oncology and vaccines portfolios and a newly launched cardiovascular drug.

Abbott Laboratories shares were falling ahead of the opening bell on Monday after a jury found the company had failed to warn that its premature baby formula could increase infants’ risk of developing a potentially deadly bowel illness.

 Drugmaker Bristol Myers Squibb posted better-than-expected second-quarter results, driven by growth from new products like anemia treatment Reblozyl and heart drug Camzyos as well as from its top-seller, blood thinner Eliquis.

Johnson & Johnson stock was slipping Wednesday after the pharmaceutical company beat expectations for its second-quarter earnings.

Novo Nordisk and Eli Lilly shares slid Wednesday after Roche announced promising early-stage trial data from its latest obesity drug candidate.